LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis. 2019

Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
Teaching Administration Office, Affiliated Hospital of Jining Medical University, Jining, People's Republic of China.

Background: Non-small cell lung cancer (NSCLC) has a significant impact on human health. The aim of this study was to explore the role of long non-coding RNA DLX6-AS1 in the proliferation, migration, and invasion of NSCLC cells. Methods: The expression of DLX6-AS1 in NSCLC tumor tissues and cell lines was examined by qRT-PCR. The effects of DLX6-AS1 knockdown on cell proliferation, migration, and invasion were assessed by Cell Counting Kit-8, wound healing, and transwell assays, respectively. Bioinformatics analyses, luciferase reporter assays, and RNA pull-down assays were employed to examine the mechanism by which DLX6-AS1 exerted its oncogenesis effects in NSCLC. The anti-tumor effect of silencing DLX6-AS1 in vivo was also evaluated. Results: DLX6-AS1 was over-expressed in NSCLC tumor tissues and cell lines and its level of expression was found to be associated with tumor size and advanced clinical stage in patients with NSCLC. Downregulation of DLX6-AS1 inhibited cell proliferation, cell clone formation, migration, and invasion of NSCLC cells. DLX6-AS1 was found to interact with miR-27b-3p/GSPT1. DLX6-AS1 expression was negatively correlated with miR-27b-3p expression, but positively correlated with GSPT1 expression in NSCLC samples. DLX6-AS1 knockdown also effectively suppressed tumor growth in an in vivo xenograft model. Conclusion: DLX6-AS1 regulated NSCLC progression by targeting the miR-27b-3p/GSPT1 axis, which may provide novel insights for NSCLC prognosis and therapy.

UI MeSH Term Description Entries

Related Publications

Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
January 2019, American journal of translational research,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
January 2022, BMC pulmonary medicine,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
January 2022, Journal of Cancer,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
May 2022, Translational cancer research,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
December 2021, Translational cancer research,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
August 2023, BMC pulmonary medicine,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
March 2022, Cancer biotherapy & radiopharmaceuticals,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
May 2020, European review for medical and pharmacological sciences,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
January 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Wen Sun, and Liwen Zhang, and Ranran Yan, and Ying Yang, and Xiangli Meng
May 2022, Neoplasma,
Copied contents to your clipboard!